Daihatsu, a car manufacturing subsidiary of Toyota Motor, is halting all its vehicle shipments due to the safety cheating scandal that it is currently facing. The company made this decision as the issue is already escalating after a recent investigation into the alleged wrongdoings revealed defects in 64 model units, including nearly two dozen vehicles sold under Toyota’s name.
The Root of the Scandal: Daihatsu’s Revelation
According to Reuters, an independent team is investigating Daihatsu after revealing in April that it had illegally interfered with the side-collision safety tests carried out for 88,000 units of small cars that the Toyota brand mostly sold. In simpler words, the automaker said it manipulated the safety test results so the vehicles passed it.
However, in the latest development regarding the case, it was suggested that the extent of the scandal is far greater than initially thought. The revelation and the recent discoveries could potentially damage Daihatsu’s reputation for safety and quality.
Result of Cheating Investigation
It was discovered that Daihatsu cheated on the safety tests on almost all the vehicle models it is currently producing and some models it produced in the past. This problem emerged after the company said in April that it found out about the improperly conducted tests through a report from a whistleblower.
Daihatsu immediately reported the matter to the regulatory agencies, and shipments of the affected vehicles were halted. Associated Press News reported that based on the results of the independent panel’s investigation, in addition to the already reported manipulated results, there are 174 new cases of irregularities in the safety tests and 25 test categories for other procedures.
“We are sorry to have betrayed the trust of our customers,” Soichiro Okudaira, president of Daihatsu, told the media on Wednesday, Dec. 20, in response to the new findings. “We take it very seriously as the problem that has shaken the foundation of an automaker.”
Photo by: Tokumeigakarinoaoshima/ Wikimedia Commons(CC BY-SA 4.0)


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Instagram Outage Disrupts Thousands of U.S. Users
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



